6 September 2019 in Nature Communications
The introduction of insertion-deletions (INDELs) by non-homologous end-joining (NHEJ) pathway underlies the mechanistic basis of CRISPR-Cas9-directed genome editing. Selective gene ablation using CRISPR-Cas9 is achieved by installation of a premature termination codon (PTC) from a frameshift-inducing INDEL that elicits nonsense-mediated decay (NMD) of the mutant mRNA. Here, by examining the mRNA and protein products of CRISPR targeted genes in a cell line panel with presumed gene knockouts, we detect the production of foreign mRNAs or proteins in ~50% of the cell lines. We demonstrate that these aberrant protein products stem from the introduction of INDELs that promote internal ribosomal entry, convert pseudo-mRNAs (alternatively spliced mRNAs with a PTC) into protein encoding molecules, or induce exon skipping by disruption of exon splicing enhancers (ESEs). Our results reveal challenges to manipulating gene expression outcomes using INDEL-based mutagenesis and strategies useful in mitigating their impact on intended genome-editing outcomes.
15 May 2015 in Molecular BioSystems
Identifying alternative indications for known drugs is important for the pharmaceutical industry. Many computational methods have been proposed for predicting unknown associations between drugs and target proteins associated with diseases. To produce better prediction, researchers should not only develop accurate algorithms but identify good features that reflect intracellular systems. In this paper, we proposed a novel method for exploiting protein localization. We generated localization vectors (LVs) from protein localization and propagated LVs through a protein interaction network to increase the coverage of the localization information. The LVs showed distinct patterns among targets of known drugs as well as independent characteristics compared to existing features. Based on the experimental results, we determined that including LVs improves cross-validation accuracy and, produces better novel predictions with real and independent clinical trial data. Moreover, the propagation of LVs showed a positive result that it can help in increasing the coverage of the prediction results.
8 April 2020 in Cancer Research
Hispanic/Latino patients have a higher incidence of gastric cancer and worse cancer-related outcomes compared with patients of other backgrounds. Whether there is a molecular basis for these disparities is unknown, as very few Hispanic/Latino patients have been included in previous studies. To determine the genomic landscape of gastric cancer in Hispanic/Latino patients, we performed whole-exome sequencing (WES) and RNA sequencing on tumor samples from 57 patients; germline analysis was conducted on 83 patients. The results were compared with data from Asian and White patients published by The Cancer Genome Atlas. Hispanic/Latino patients had a significantly larger proportion of genomically stable subtype tumors compared with Asian and White patients (65% vs. 21% vs. 20%, P < 0.001). Transcriptomic analysis identified molecular signatures that were prognostic. Of the 43 Hispanic/Latino patients with diffuse-type cancer, 7 (16%) had germline variants in CDH1. Variant carriers were significantly younger than noncarriers (41 vs. 50 years, P < 0.05). In silico algorithms predicted five variants to be deleterious. For two variants that were predicted to be benign, in vitro modeling demonstrated that these mutations conferred increased migratory capability, suggesting pathogenicity. Hispanic/Latino patients with gastric cancer possess unique genomic landscapes, including a high rate of CDH1 germline variants that may partially explain their aggressive clinical phenotypes. Individualized screening, genetic counseling, and treatment protocols based on patient ethnicity and race may be necessary.Significance: Gastric cancer in Hispanic/Latino patients has unique genomic profiles that may contribute to the aggressive clinical phenotypes seen in these patients.
1 December 2013 in Computers in Biology and Medicine
11 July 2018 in Cancer Reports
Background: Wilms tumor and rhabdoid tumor can have similar clinical presentations, but they have distinct histological and biological features. For instance, Wilms tumors commonly bear mutations in kidney differentiation or microRNA processing genes, whereas rhabdoid tumor is characterized by loss of SMARCB1.Aims: We initially set out to characterize and identify tumor suppressor microRNAs in WT‐CLS1, which had been described as a Wilms tumor cell line.Methods and Results: We characterized the cell line WT‐CLS1 by whole exome sequencing, RNA‐seq, and xenograft histology. We measured the effect of microRNA overexpression on WiT49, WT‐CLS1, BT‐12, and CHLA‐06‐ATRT.We found that miR‐16 significantly impairs cell proliferation in WT‐CLS1 by repressing numerous cell cycle genes, including the D‐type cyclins. In addition, we found that the WT‐CLS1 cell line demonstrates the classic histological, mutational, and transcriptional hallmarks of rhabdoid tumor, including SMARCB1 loss. Lastly, miR‐16 also represses cell cycle genes and impairs proliferation in the BT‐12 and CHLA‐06‐ATRT rhabdoid tumor cell lines.Conclusions: The loss of SMARCB1 warrants reclassification of WT‐CLS1 as rhabdoid tumor. Overexpression of miR‐16 significantly abrogates proliferation of WT‐CLS1 and other rhabdoid tumor cell lines. Further studies are necessary to gain insight into the potential for miR‐16 to be a tumor suppressor or a novel therapeutic in rhabdoid tumor.